Continuing LBPD is a viable treatment option for select patients with ALK-positive NSCLC who progressed on lorlatinib. READ ARTICLE
Journal of Thoracic Oncology DOI:10.1016/j.jtho.2021.12.011
Authors: Sai-Hong I.Ou, Benjamin J.Solomon, Alice T.Shaw, Shirish M.Gadgeel, BenjaminBesse, Ross A.Soo, Antonello Abbattista, Francesca Toffalorio, Robin Wiltshire, Alessandra Bearz
